Each tablet contains: N-Acetyl-L-Cysteine 200 mg • Bromelain (Ananas comosus) (Pineapple Stem) (1500 MCU) 100 mg • Marshmallow extract 4:1 (Althaea officinalis) (root) 100 mg • Mullein extract 4:1 (Verbascum thapsus) (leaf) 100 mg • Wild Cherry extract 4:1 (Prunus serotina) (bark) 100 mg • Horehound extract 4:1 (Marrubium vulgare) (herb) 50 mg • Ivy extract (Hedera helix) (leaf) 50 mg, Hederocoside (10%) 5 mg. Other Ingredients: Microcrystalline Cellulose, Crsocarmellose Sodium, Coating (Carbohydrate Gum [Cellulose], Glycerin), Magnesium Stearate (Vegetable Grade).
Brand name products often contain multiple ingredients. To read detailed information about each ingredient, click on the link for the individual ingredient shown above.
Below is general information about the effectiveness of the known ingredients contained in the product Lung, Bronchial & Sinus Health. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
There is insufficient reliable information available about the effectiveness of wild cherry.
Below is general information about the safety of the known ingredients contained in the product Lung, Bronchial & Sinus Health. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
POSSIBLY SAFE ...when used orally and appropriately. Doses up to 240 mg daily have been used safely for up to a year (6252,6253,10622,11457,18281,18284,91104,91105,91106,91111)(96449,103298). Higher doses up to 3200 mg daily have been used safely, short-term (18283,110546). ...when used topically and appropriately. Bromelain has been used safely as a debriding agent for up to 4 hours (18275,91113,103297,108148,108149).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
POSSIBLY SAFE ...when the leaf extract is used orally and appropriately, short-term. Two specific products containing dried English ivy leaf extract 7 mg/mL (Prospan, PendoPharm; Prospanex, Engelhard Arzneimittel GmbH and Co. KG), taken in doses of 7.5 mL three times daily, have been used with apparent safety for up to 7 days (29903,106055). There is insufficient reliable information available about the safety of topical English ivy.
CHILDREN: POSSIBLY SAFE
when the leaf extract is used orally and appropriately, short-term.
Two specific products containing dried English ivy leaf extract 7 mg/mL (Prospan, PendoPharm; Prospanex, Engelhard Arzneimittel GmbH and Co. KG), taken in doses of 2.5-7.5 mL three times daily, has been used with apparent safety for up to 7 days in infants and children up to 18 years of age (29903,106055).
PREGNANCY:
Insufficient reliable information available; avoid using.
A small retrospective study suggests that taking English ivy leaf extract at an unknown dose or duration during pregnancy is not associated with changes in pregnancy duration, the rate of preterm birth, infant health complications, or infant deaths (110402). However, due to its small size, retrospective design, and insufficient information regarding dose and duration, further research is needed to determine the safety of English ivy during pregnancy.
LACTATION:
Insufficient reliable information available; avoid using.
LIKELY SAFE ...when marshmallow root and leaf are used in amounts commonly found in foods. Marshmallow root has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).
POSSIBLY SAFE ...when marshmallow root and leaf are used orally in medicinal amounts (4,12). ...when used topically (4,62020). There is insufficient reliable information available about the safety of marshmallow flower.
PREGNANCY AND LACTATION:
Insufficient reliable information available.
LIKELY SAFE ...when used orally, intravenously, intratracheally, or by inhalation and appropriately. N-acetyl cysteine is an FDA-approved prescription drug (832,1539,1705,1710,2245,2246,2252,2253,2254,2256)(2258,2259,2260,5808,6176,6611,7868,10270,10271,16840)(91243,91247,102027,102660,102666,99531).
CHILDREN: LIKELY SAFE
when used orally and appropriately.
N-acetyl cysteine has been safely used at doses of 900-2700 mg daily for 8-12 weeks (91235,91239,91241,102666). ...when used intravenously and appropriately. Intravenous N-acetyl cysteine 140 mg/kg/day plus oral N-acetyl cysteine 70 mg/kg four times daily for up to 10 months has been safely used (64547).
PREGNANCY: POSSIBLY SAFE
when used orally, intratracheally, intravenously, or by inhalation.
N-acetyl cysteine crosses the placenta, but has not been associated with adverse effects to the fetus (1711,64615,64493,97041). However, N-acetyl cysteine should only be used in pregnancy when clearly indicated, such as in cases of acetaminophen toxicity.
LACTATION:
Insufficient reliable information available; avoid using.
LIKELY SAFE ...when used orally in amounts commonly found in foods. White horehound has Generally Recognized as Safe (GRAS) status in the US (4912).
POSSIBLY SAFE ...when used orally and appropriately (2,12).
POSSIBLY UNSAFE ...when used orally in excessive amounts; white horehound may have a purgative effects (4,12). There is insufficient reliable information available about the safety of the topical use of white horehound.
PREGNANCY: LIKELY UNSAFE
when used orally; white horehound might have abortifacient effect (19), or stimulate menstrual flow and the uterus (12).
There is insufficient reliable information available about the safety of topical use during pregnancy; avoid using.
LACTATION:
There is insufficient reliable information available about the safety of oral use during lactation; avoid amounts greater than those commonly found in foods.
There is insufficient reliable information available about the safety of topical use during lactation; avoid using.
LIKELY SAFE ...when used orally in amounts commonly found in foods and beverages. Wild cherry has Generally Recognized as Safe (GRAS) status in the US (4912).
POSSIBLY SAFE ...when used orally and appropriately short-term, in limited amounts (12).
POSSIBLY UNSAFE ...when used orally and long-term or in excessive amounts (12,19). The constituent prunasin hydrolyzes to hydrocyanic acid (HCN) (11,12,13,18).
PREGNANCY: LIKELY UNSAFE
when used orally because prunasin is potentially teratogenic (19).
LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Lung, Bronchial & Sinus Health. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Bromelain may have antiplatelet effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
 Details
There is one case report of a patient experiencing minor bruising while taking bromelain with naproxen (14806). Bromelain is thought to have antiplatelet activity (10639,14806,18285,18286,37234). Whether this interaction is of concern with topical bromelain is unclear. Interference with coagulation of burn wounds has been reported in a patient receiving bromelain-based enzymatic debridement. However, observational research has found that topical bromelain debridement is not associated with increases or decreases in laboratory markers of coagulation when compared with surgical debridement (110547).
|
Theoretically, bromelain might increase levels of tetracycline antibiotics.
Details
Laboratory research suggests that bromelain might increase the absorption of tetracycline antibiotics. However, a study in healthy adults reported no difference in tetracycline plasma levels when a 500 mg dose was taken with or without bromelain 80 mg (14296).
|
Theoretically, English ivy might increase the levels of drugs metabolized by CYP2C19.
Details
In vitro research shows that English ivy inhibits CYP2C19 enzymes (96682). So far, this interaction has not been reported in humans.
|
Theoretically, English ivy might increase the levels of drugs metabolized by CYP2C8.
Details
In vitro research shows that English ivy inhibits CYP2C8 enzymes (96682). So far, this interaction has not been reported in humans.
|
Theoretically, English ivy might increase the levels of drugs metabolized by CYP2D6.
Details
In vitro research shows that English ivy inhibits CYP2D6 enzymes (96682). So far, this interaction has not been reported in humans.
|
Theoretically, marshmallow flower might have antiplatelet effects.
Details
Animal research suggests that marshmallow flower extract has antiplatelet effects (92846). However, the root and leaf of marshmallow, not the flower, are the plant parts most commonly found in dietary supplements. Theoretically, use of marshmallow flower with anticoagulant/antiplatelet drugs can have additive effects, and might increase the risk for bleeding in some patients.
|
Theoretically, due to potential diuretic effects, marshmallow might reduce excretion and increase levels of lithium.
Details
Marshmallow is thought to have diuretic properties. To avoid lithium toxicity, the dose of lithium might need to be decreased when used with marshmallow.
|
Theoretically, mucilage in marshmallow might impair absorption of oral drugs.
Details
|
N-acetyl cysteine might reduce the effects of activated charcoal, while activated charcoal might reduce the absorption of N-acetyl cysteine.
Details
N-acetyl cysteine appears to reduce the capacity of activated charcoal to adsorb acetaminophen and salicylic acid (7869). Conversely, although clinical research suggests that although activated charcoal can reduce the absorption of N-acetyl cysteine by up to 40%, it does not seem to reduce its clinical effects (1755,22774,22775,64501,64647). Other clinical evidence suggests that activated charcoal does not affect the absorption of N-acetyl cysteine (22776,22777).
|
Theoretically, N-acetyl cysteine might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.
Details
Clinical research suggests that intravenous N-acetyl cysteine decreases prothrombin time, prolongs coagulation time, decreases platelet aggregation, and increases blood loss in surgical patients (64511,64644). Furthermore, in vitro research suggests that N-acetyl cysteine increases the anticoagulant activity of nitroglycerin (22780,64780).
|
Theoretically, N-acetyl cysteine might increase the risk of hypotension when taken with antihypertensive drugs.
Details
Animal research suggests that N-acetyl cysteine potentiates the hypotensive effects of the angiotensin-converting enzyme inhibitors (ACEIs) captopril and enalaprilat (22785). Theoretically, combining N-acetyl cysteine with other antihypertensive drugs might increase the risk of hypotension.
|
Theoretically, N-acetyl cysteine might interfere with the antimalarial effects of chloroquine.
Details
Animal research suggests that N-acetyl cysteine might reduce the antimalarial effects of chloroquine by increasing cellular levels of glutathione (22786).
|
N-acetyl cysteine can increase the risk for hypotension and headaches when taken with intravenous or transdermal nitroglycerin.
Details
Clinical research shows that concomitant administration of N-acetyl cysteine and intravenous or transdermal nitroglycerin can cause severe hypotension (2246) and intolerable headaches (2245,2280). Furthermore, in vitro research suggests that N-acetyl cysteine increases the anticoagulant activity of nitroglycerin (22780,64780).
|
Evidence from animal research suggests that white horehound might lower blood glucose (23603,26149). However, preliminary clinical research suggests that white horehound only slightly lowers blood glucose when taken in combination with antidiabetic agents, suggesting that the effect may not be clinically significant (86369). Until more is known, use with caution. Theoretically, white horehound may have additive effects when used by patients taking antidiabetic drugs. The dose of diabetes medications might need to be adjusted. Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.
|
Evidence from animal research suggests that taking white horehound extract lowers blood pressure (49408,86367). Theoretically, taking white horehound with antihypertensive drugs might enhance therapeutic effects and increase the risk of hypotension. Some antihypertensive drugs include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.
|
In vitro research suggests that wild cherry can inhibit cytochrome P450 3A4 (CYP3A4) enzymes (6450). Theoretically, wild cherry might increase levels of drugs metabolized by CYP3A4. However, so far, this interaction has not been reported in humans.
Details
Some drugs metabolized by CYP3A4 include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and others.
|
Below is general information about the adverse effects of the known ingredients contained in the product Lung, Bronchial & Sinus Health. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally, bromelain seems to be well tolerated.
Most Common Adverse Effects:
Orally: Diarrhea, flatulence, gastric upset, headache.
Topically: Pruritus, urticaria.
Dermatologic
...Topically, bromelain may cause dermal allergic reactions including urticaria, pruritus, and skin swelling (9184).
Redness, swelling, burning, pain at the application site, and cellulitis have also been reported rarely (108148,113513). In one case, a fixed drug eruption with pruritis near the groin was reported in a 33-year-old male taking bromelain 50 mg orally daily for 10 days. After discontinuation of bromelain and treatment with topical corticosteroid, the lesion resolved. Upon re-challenge with bromelain, the lesion reappeared in the same area (103300).
In another case report, a 61-year-old male with a history of chronic lower leg ulceration secondary to chronic venous hypertension and recurrent deep vein thrombosis on rivaroxaban presented with a deep-dermal burn on his lower calf. Bromelain-based topical enzymatic debridement agent Nexobrid 2 grams was applied to the burn site. Thirty minutes later, the patient experienced two instances of hemorrhage at the site of debridement. The patient was stabilized and treated with fluids, packed red cells, and tranexamic acid, and then the Nexobrid was removed (111656). Caution should be used in patients with underlying coagulopathies.
Gastrointestinal ...Orally, bromelain may cause gastrointestinal disturbances, including diarrhea, nausea, vomiting, flatulence, and abdominal pain (9184,18274,18282,96216,113513).
Immunologic
...Immunoglobulin E (IgE)-mediated allergic reactions to bromelain may occur (9184).
If inhaled, bromelain may cause sensitization and allergic reactions such as asthma (37199,37215,37233). In case reports of occupational inhalation of bromelain, additional allergic symptoms included difficulty swallowing, throat itching, eye irritation, and rhinitis (37214).
General
...Orally and topically, English ivy leaf extract seems to be generally well tolerated.
Most Common Adverse Effects:
Orally: Abdominal pain, diarrhea, nausea, skin irritation, vomiting.
Topically: Allergic reactions, contact dermatitis.
Dermatologic
...Orally, English ivy and fresh English ivy leaves can cause skin irritation (7,29903).
Topically, fresh English ivy leaves can cause contact dermatitis and rash, with frequent exposure increasing the risk of sensitization (29910,29912,29913,29914,91301,96620,96636,96681). Occupational airborne exposure to English ivy can also cause contact dermatitis (96600).
Gastrointestinal ...Orally, English ivy can cause abdominal pain, diarrhea, nausea, and vomiting (29903,106055). The saponin constituents of English ivy can produce an acrid and/or bitter taste (7).
General ...Orally and topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.
General ...Information regarding the adverse effects of mullein is limited. A thorough evaluation of safety outcomes has not been conducted.
Dermatologic ...Two case reports have described dermatitis, with positive patch tests, after topical exposure to the whole plant, or by occupational inhalation of plant dust (92839,97316). In the case of topical exposure, the patient also had positive patch tests to other plants.
General
...Orally, intravenously, and as an inhalation, N-acetyl cysteine is generally well-tolerated when used in typical doses.
Most adverse effects to N-acetyl cysteine occur when single doses of greater than 9 grams are used or when a regimen of greater than 30 grams daily is followed.
Most Common Adverse Effects:
Orally: Diarrhea, dry mouth, dyspepsia, heartburn, loss of appetite, nausea, and vomiting.
Intravenously: Skin rash and hypersensitivity reactions.
Inhaled: Bronchospasm, cough, epigastric pain, throat irritation, and wheezing.
Serious Adverse Effects (Rare):
Orally: Chest tightness, hemoptysis, and palpitations have been reported.
Intravenously: Anaphylaxis, angina, dystonic reactions, tachycardia, and transient sinus bradycardia have been reported.
Cardiovascular
...Intravenously, N-acetyl cysteine has been reported to significantly increase systolic and diastolic blood pressure after exposure to nitroglycerin when compared with placebo (2280).
Tachycardia, chest pain, angina, and transient sinus bradycardia have been rarely reported after administration of intravenous N-acetyl cysteine (2280,7872,64658).
Intratracheally, infants receiving 5% N-acetyl cysteine every four hours for chronic lung disease have developed bradycardia (64490).
Orally, palpitations and chest tightness have been reported rarely in clinical research evaluating oral N-acetyl cysteine at doses up to 600 mg twice daily (64675,64717,64762).
Dermatologic
...Orally, N-acetyl cysteine may cause hives (64713,64739,64813), flushing (2260,64715), and edema (64714).
Rash has also been reported (64510,64715,64717,102656). In one study, flushing was reported in 2% of patients receiving 600 mg of N-acetyl cysteine orally twice daily for six months (2260).
Intravenously, N-acetyl cysteine may cause rash, and the occurrence seems to be more common than with oral use (2254,64492,64562,64658,64759,64794). Hives (2280,64794), facial edema (2280), flushing (64412), and pruritus (64658,64763) have also been reported. In a small case series of 10 healthy male patients receiving 150 mg/kg of intravenous N-acetyl cysteine for muscle fatigue, erythema was experienced 30 minutes after infusion. Other side effects reported by these patients include facial erythema, palmar erythema, and sweating (64763). In other clinical research, three patients developed an erythematous flare at the sites of previous venipunctures after receiving 5.5 gm/m2 of N-acetyl cysteine with doxorubicin therapy (64712). Pain, inflammation, and excoriation of the skin have been reported after a 20% N-acetyl cysteine solution leaked from the catheter in one patient (64726).
Gastrointestinal
...Orally, gastrointestinal complaints are the most common adverse effects reported with N-acetyl cysteine.
These include heartburn (64608,64715,64717,64738,64739,102666), dyspepsia (1710,64715,64717,64724,64738), and epigastric pain (2260,10429,64715,64717). In one case report, esophagitis related to ulcerations occurred following intake of N-acetyl cysteine while in the supine position with inadequate water (102655). Other common side effects include loss of appetite (64715,64812), flatulence (2256,64510), diarrhea (64713,64715,97049), constipation (64715), dry mouth (64715,64724), nausea (7868,11430,64715,64724,64738,64812,97049), vomiting (64717,64724,64715,97049), gastric upset (64510,64545,97045,97049), acid reflux (108450), changes in bowel habits (108450), and intolerance to taste and odor (64510,64545). N-acetyl cysteine's unpleasant odor makes it difficult for some patients to take orally. Using a straw to drink N-acetyl cysteine solutions can improve tolerability. Additionally, placement of a nasogastric or duodenal tube and administration of metoclopramide or ondansetron can be helpful for patients unable to tolerate oral N-acetyl cysteine (17).
Intravenously, N-acetyl cysteine may cause diarrhea (64712), dyspepsia, nausea, vomiting (64763), mild gastrointestinal upset (102657), and metallic taste (64763).
When inhaled, N-acetyl cysteine may cause epigastric pain and throat irritation (64703,64707,64674).
Genitourinary ...Orally, dysuria was reported in 2% of patients receiving 600 mg of N-acetyl cysteine twice daily for 6 months in one clinical trial (2260).
Hematologic
...In general, hematologic adverse reactions are reported more frequently with intravenous N-acetyl cysteine compared with oral use.
In surgical patients, decreased prothrombin time (1341,64511), prolonged coagulation time (64511), increased blood loss (64511,64644), and decreased platelet aggregation (64511) have been reported after administration of IV N-acetyl cysteine. In one clinical trial, six healthy patients were administered a loading dose of IV N-acetyl cysteine 10 mg/kg followed by 10 mg/kg per hour for 32 hours. All patients experienced a decrease in prothrombin time by 30% to 40%. The decrease prothrombin time (25.4 sec to 20.6 sec) reached a steady state after 16 hours (1341). In a clinical trial evaluating patients with acute myocardial infarction, hemorrhage occurred in three patients taking intravenous N-acetyl cysteine 10 mg/min, heparin (per study protocol), and aspirin (7872). Two pediatric patients receiving intravenous N-acetyl cysteine (loading dose: 140 mg/kg followed by 70 mg/kg) experienced episodes of coagulopathy; however, patients were being treated for acetaminophen overdose (64794).
Hemoptysis was reported in six patients receiving 200 mg of N-acetyl cysteine orally twice daily for 6 months for treatment of chronic bronchitis (64739).
Immunologic
...Orally, anaphylaxis to N-acetyl cysteine has been rarely reported (64794).
However, anaphylactic reactions to intravenous N-acetyl cysteine appear to be more common (1716,64412,64449,64628,64710,64711,64721,64786,64789).
Anaphylactic reactions to N-acetyl cysteine have involved rash, angioedema, hypotension, and bronchospasm (64449,64711,64720). The mechanism of this reaction is unclear, but some data suggest it is not an immunologic hypersensitivity reaction but rather an acute toxic effect of N-acetyl cysteine (64786,64641,64720). Management guidelines for the treatment of anaphylactoid reactions to intravenous N-acetyl cysteine have been published. In most cases, treatment is not required or treatment with diphenhydramine or salbutamol is sufficient to continue or restart N-acetyl cysteine infusion. Antihistamines are useful in controlling and preventing recurrence of anaphylactoid symptoms (1716).
Musculoskeletal ...In one clinical trial, joint pain was reported in more than 15% of patients receiving oral N-acetyl cysteine (64608). In other research, one patient experienced pain in the legs while taking 600 mg of N-acetyl cysteine twice daily for the treatment of chronic bronchitis (64762).
Neurologic/CNS
...Orally, headache has been frequently reported with N-acetyl cysteine in clinical research (7873,11430,64510,64608,64672,64713,64715,64724,64762).
Other less common adverse effects reported in patients taking oral N-acetyl cysteine at a total daily dose of 600-1200 mg include dizziness (64715,64717,64724,64762), tiredness (64675,64717), vivid dreams (102666), disorientation, and inability to concentrate (64673). One pediatric patient receiving oral N-acetyl cysteine (loading dose: 140 mg/kg followed by 70 mg/kg) experienced encephalopathy (64794).
Intravenously, N-acetyl cysteine has been associated with rare neurologic adverse reactions , including headache (7872), lightheadedness (64763), and dystonic reactions (64794). In a previously healthy 2-year-old female, status epilepticus occurred during intravenous N-acetyl cysteine therapy for paracetamol ingestion (64781). Increased deterioration in bulbar function in patients with amyotrophic lateral sclerosis has also been reported with IV N-acetyl cysteine (2254).
Ocular/Otic ...While rare, blurred vision has been reported in research on oral N-acetyl cysteine (64715). Additionally, in a previously healthy 2-year-old female, status epilepticus followed by cortical blindness occurred during intravenous N-acetyl cysteine therapy for paracetamol ingestion. In this case, vision was almost completely recovered 18-months later (64781).
Psychiatric ...Intravenously, dysphoria was experienced 30 minutes after infusion of N-acetyl cysteine in 8 of 10 healthy males assessed in one clinical study (64763).
Pulmonary/Respiratory
...Respiratory adverse reactions to N-acetyl cysteine are most commonly reported with inhalable dosage forms.
These include wheezing (64455,64707), bronchospasm (64455,64699), and cough (64455,64456,64703,64811). While less frequent, wheezing (64675), bronchospasm (64675), increased sputum production (7868), cough (7868,64510), decreased peak flow (64510), dyspnea (64714), and cold symptoms (64510) have been reported with oral N-acetyl cysteine in clinical research. A few cases of wheezing (64718,64719), cough (64763), and bronchospasm (64658) have also been reported with intravenous N-acetyl cysteine. Additionally, respiratory arrest has been reported in one case where a 16 year-old female was being treated for acetaminophen toxicity with intravenous N-acetyl cysteine (64450).
Two premature infants receiving 5% N-acetyl cysteine via intratracheal instillation for the treatment of chronic lung disease had an increased frequency of cyanotic spells (64490).
Other ...Injection site reactions, including burning and phlebitis, have been reported in patients receiving IV N-acetyl cysteine (1341,64763). Fever associated with IV N-acetyl cysteine was reported in one patient during clinical research (64759).
General
...Orally, white horehound may cause nausea, dry mouth, excessive salivation, loss of appetite, and dizziness in some patients (86369).
Large amounts of white horehound (exact dose is unclear) may cause purgative effects (4,12).
Topically, skin contact with the plant juice may cause contact dermatitis (4).
Dermatologic ...Topically, skin contact with the plant juice may cause contact dermatitis (4).
Gastrointestinal ...Orally, clinical research shows that drinking one cup of tea prepared with white horehound 1 gram three times daily for 3 weeks may cause nausea, dry mouth, excessive salivation, and loss of appetite in some patients (86369). Intake of large amounts of white horehound (exact dose is unclear) may cause purgative effects (4,12).
Neurologic/CNS ...Orally, clinical research shows that drinking one cup of tea prepared with white horehound 1 gram three times daily for 3 weeks may cause dizziness in some patients (86369).
General ...Orally, large amounts of wild cherry can lead to cyanide toxicity, which can be fatal (18,41565).
Neurologic/CNS ...Orally, large amounts of wild cherry can lead to cyanide toxicity, which can be fatal (18,41565). A case of accidental poisoning has been reported for a 56-year old women who consumed approximately 300 grams of wild cherries that had been steeped in alcohol the evening before symptom onset. The patient presented to the hospital the following day with symptoms including headache, nausea, vomiting, confusion, and severe dyspnea. Eventually the patient became comatose and hypotonic. After regaining consciousness the following day, the patient continued to experience severe sinus bradycardia, as well as disorientation, hallucinations, delusions, and agitation. After about 3 weeks, the patient began to experience blurred vision and tingling sensation of the lower limbs. The symptoms were eventually attributed to cyanide intoxication; the wild cherries the patient had consumed contained 4.7-15 mg/kg cyanide (41565).
